We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.43B
AUM Growth
-$499M
Cap. Flow
-$449M
Cap. Flow %
-31.45%
Top 10 Hldgs %
64.34%
Holding
48
New
3
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
+$81.4M
2
TRVI icon
Trevi Therapeutics
TRVI
+$38.1M
3
GNCA
Genocea Biosciences, Inc.
GNCA
+$14.9M
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$3.72M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$1.75M

Top Sells

Rank Stock Value
1
ESTC icon
Elastic
ESTC
+$444M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$70.7M
3
EPZM
Epizyme, Inc
EPZM
+$32.2M
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$30.8M
5
ARQL
Arqule Inc
ARQL
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.45%
2 Industrials 1.15%
3 Technology 0.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARX
1
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$185M 12.93%
6,138,797
– –
CBIO
2
Crescent Biopharma
CBIO
$567M
$108M 7.59%
90,890
– –
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$7.35B
$108M 7.57%
4,912,306
– –
CRSP icon
4
CRISPR Therapeutics
CRSP
$4.63B
$98.5M 6.9%
2,090,678
– –
ALLK
5
DELISTED
Allakos
ALLK
$98.3M 6.88%
2,268,188
– –
PHAS
6
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$87.2M 6.11%
+6,643,704
New +$81.4M
ADAP
7
DELISTED
Adaptimmune Therapeutics
ADAP
$63.6M 4.46%
15,832,611
– –
SENS icon
8
Senseonics Holdings Inc
SENS
$258M
$63M 4.41%
1,544,413
– –
EPZM
9
DELISTED
Epizyme, Inc
EPZM
$54.9M 3.85%
4,377,518
-2,500,000
-36% -$32.2M
OBSV
10
DELISTED
ObsEva SA Ordinary Shares
OBSV
$51.9M 3.63%
4,586,563
– –
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
$48.2M 3.37%
475,771
– –
ARDX icon
12
Ardelyx
ARDX
$1.24B
$41.3M 2.89%
15,335,047
– –
MRKR icon
13
Marker Therapeutics
MRKR
$19.7M
$39.6M 2.77%
500,000
– –
SYBX
14
DELISTED
Synlogic
SYBX
$38.5M 2.7%
281,961
– –
AUPH icon
15
Aurinia Pharmaceuticals
AUPH
$1.92B
$34M 2.38%
5,172,683
– –
DERM
16
DELISTED
Dermira, Inc.
DERM
$33.5M 2.35%
3,506,649
– –
TRVI icon
17
Trevi Therapeutics
TRVI
$2.53B
$33.2M 2.33%
+4,429,804
New +$38.1M
GNCA
18
DELISTED
Genocea Biosciences, Inc.
GNCA
$28.3M 1.98%
7,225,676
+2,857,142
+65% +$14.9M
TPST icon
19
Tempest Therapeutics
TPST
$14.2M
$20.4M 1.43%
9,060
– –
LQDA icon
20
Liquidia Corp
LQDA
$7.64B
$19.9M 1.39%
2,486,062
– –
AVEO
21
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$16.9M 1.18%
2,524,387
+434,783
+21% +$3.72M
BE icon
22
Bloom Energy
BE
$45.6B
$16.4M 1.15%
1,333,333
– –
LXRX icon
23
Lexicon Pharmaceuticals
LXRX
$1.03B
$15M 1.05%
2,382,286
– –
AFMD
24
DELISTED
Affimed
AFMD
$14.7M 1.03%
513,889
– –
LITS
25
Lite Strategy Inc
LITS
$32.4M
$14.3M 1%
286,029
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q2 2019 Portfolio in Review

As of Q2 2019, NEA Management Company held 48 positions worth $1.43B, down 26% from $1.93B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

NEA Management Company withdrew a net $449M in Q2 2019, closing 4 positions and reducing 1 holding. Its most notable exit was Elastic, an estimated $444M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 73% a quarter earlier, followed by Industrials and Technology.

Against the trend, NEA Management Company opened a new position in PhaseBio Pharmaceuticals, Inc. Common Stock worth $87.2M.

  • NEA Management Company's largest Q2 2019 buy was PhaseBio Pharmaceuticals, Inc. Common Stock: 6,643,704 shares worth $87.2M.
  • NEA Management Company added most to Genocea Biosciences, Inc. in Q2 2019, an estimated $14.9M increase.
  • NEA Management Company's biggest Q2 2019 reduction was Epizyme, Inc, cutting an estimated $32.2M.
  • NEA Management Company fully exited Elastic in Q2 2019, selling an estimated $444M.
  • NEA Management Company's ten largest holdings make up 64% of its $1.43B portfolio in Q2 2019.
  • NEA Management Company opened 3 new positions and closed 4 in Q2 2019.
  • NEA Management Company's portfolio value fell 26% quarter-over-quarter to $1.43B.

Based on NEA Management Company's 13F filing for Q2 2019, filed 7 Aug 2019.